Appointment of Chief Business Officer

e-therapeutics plc (AIM: ETX.L, "e-therapeutics" or "the Company") today announces the appointment of Dr Laura Roca-Alonso as Chief Business Officer.

Dr Roca-Alonso brings a depth of strategic expertise in advanced therapeutics and platform technologies, encompassing corporate and business development, portfolio strategy, business planning, competitive intelligence and communications. From 2014 until 2019, she held positions of increasing responsibility at Silence Therapeutics, a publicly listed RNAi company, culminating in her role as VP, Head of Corporate Development. During her time at Silence Therapeutics, she was instrumental in the transformation and growth of the business. Most recently, Laura served as Director of Business Development at Gyroscope Therapeutics, a Syncona-backed clinical-stage retinal gene therapy company. Laura received her Ph.D. from Imperial College London, an MRes Biomedicine from University College London and her BSc (hons) in Biotechnology from Universitat Autonoma de Barcelona. 

e-therapeutics has built an impressive network biology-based discovery capability that is being leveraged to gain actionable insights into complex disease and to enable early-stage drug discovery in areas of high unmet need. I am excited to be joining the team at this important time for the company to help maximise the value of its unique platform technologies.

Dr Roca-Alonso

Chief Business Officer

We are delighted to welcome Laura to the team at e-therapeutics. Her broad experience will be a great asset as we continue to build the company.

Ali Mortazavi

Executive Chairman